A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
Market Scope
Trusted Global Partner of Industry and Medical Professionals for Ophthalmic Market Research, Primary Research, Independent Perspective, & Objective Analysis
Choose Your Experience
Over 500 Clients, Large & Small from Around the World, Trust Market Scope Data & Analysis
Latest Market Reports
Market Scope's industry reports are meticulously prepared by a dedicated team of in-house consultants/analysts with over 100 years of collective experience.
- 269
Comprehensive Pages
- 8
Geographic and Economic Breakouts
- 5
Year Market Forecasts
- 52
Diseases Analyzed
2025 Cornea Products Market Report: Global Analysis for 2024 to 2030, December, 2025
The “2025 Cornea Products Market Report” delivers an in-depth analysis of the global cornea market, highlighting the latest advances in transplantation, crosslinking, and therapeutic devices aimed at restoring and preserving vision. The report estimates disease prevalence across six major corneal conditions and examines evolving treatment approaches, including cornea transplants, therapeutic lenses, phototherapeutic keratectomy (PTK), intrastromal ring segments, and corneal crosslinking.
It also explores the global ecosystem that supports cornea care—spanning organ donation systems, regulatory environments, and the pivotal roles of cornea specialists, eye banks, and nonprofit organizations.
This 2025 edition evaluates more than 70 products from over 50 companies, with forecasts for unit demand and revenue growth through 2030. It features analysis of emerging pipeline technologies yet to generate revenue and profiles 12 leading market participants shaping the future of cornea treatment.
Latest Industry News & Trends
7/31/2026
BreakingPharmaRegulationRetina
US FDA Approves Outlook’s Lytenava (Bevacizumab) for Wet AMD
Outlook Therapeutics announced July 24 that it had gained US FDA approval for Lytenava (bevacizumab-vikg) to treat wet age-related macular degeneration (AMD). The news comes after years of regulato...
7/31/2026
BreakingGlaucomaRegulationSurgical
Glaukos Changes US Regulatory Pathway for PreserFlo, Completes Enrollment in 510(k) Study
Glaukos reported July 27 that it had completed patient enrollment in a 510(k) pivotal study for the PreserFlo MicroShunt. The glaucoma drainage device is implanted ab externally to increase outflow...
7/31/2026
BreakingCataractCornealDry EyeGene TherapyGlaucomaIOLMIGSPharmaRetinaRevenueSurgical
Q2-2026 Ophthalmic Revenue Roundup for Bausch + Lomb, Roche, and Glaukos
Bausch + Lomb reported July 29 that its Q2-2026 revenue was $1.4 billion, a 9 percent increase over $1.3 billion in Q2-2025, driven by a 64 percent increase in implantables, including a 175 percent...
7/31/2026
BreakingEuropeLow VisionRetina
Science Corp. Launches Prima Retinal Implant in Europe
Science Corporation reported July 22 that it had launched its Prima retinal implant in Europe for patients with geographic atrophy (GA) caused by age-related macular degeneration (AMD). The company...
7/31/2026
BreakingCataractIOLPremiumSurgical
Bausch + Lomb Launches EyeGility Preloaded IOL Inserter in the US
Bausch + Lomb announced July 16 that it had launched the EyeGility Inserter preloaded IOL (intraocular lens) delivery system in the US. The inserter is available now with the enVista Aspire interme...
7/31/2026
BreakingDealsPresbyopiaRegulation
Marketing Application Submitted in Australia for Orasis’ Presbyopia Drop
Orasis Pharmaceuticals announced July 15 that its partner Aspen Australia had submitted a new drug application to Australia’s Therapeutic Goods Administration for Orasis’ pilocarpine hydrochloride ...
7/31/2026
AllergyBreakingDeals
Santen and Kyorin to Jointly Market Eyelid Cream for Allergic Conjunctivitis in Japan
Japanese pharmaceutical companies Santen and Kyorin announced July 13 that they would jointly market Santen’s Alesion long-acting eyelid cream (epinastine hydrochloride 0.5%) for allergic conjuncti...
7/31/2026
BreakingGene TherapyRegulationRetina
Atsena’s Gene Therapy Candidates for XLRS, LCA1 Gain EMA Orphan Designation
Atsena Therapeutics announced July 23 that the European Medicines Agency (EMA) had granted orphan designation to its two clinical-stage gene therapy candidates: ATSN-101 for Leber congenital amauro...
Provider Surveys & Interviews
Grab a seat at the table and join the thousands of ophthalmologists and optometrists from over 60 countries who are helping shape the next generation of diagnostics, pharmaceuticals, devices, and equipment by sharing your opinion and experience. Make your voice heard!
Choose Your Own Adventure
Participation options include weekly polls, special sponsored surveys, syndicated quarterly surveys, focus groups, and interviews, each with varying levels of honoraria.
Safe, Secure & On Any Device
We follow all industry standards to ensure confidentiality between participants and clients. Start and stop surveys anytime on our free Market Scope+ App or on desktop, each with a personalized dashboard just for you.
Pre-Qualified Invitations
We individually verify all potential participants before each survey or interview, ensuring that only licensed eye care professionals are invited and they are never kicked out or disqualified.
Better Data = Better Decisions
A team of industry experts and analysts review each data point, so you can be confident in the results and trends provided in our reports.
Download the Market Scope+ app to get started!
Market Scope Methodology
A Multi-Step Approach for Accurate & Timely Data
Proprietary data
- 20+ years of physician survey data
- Disease models
- Cultivated database of physicians, ASCs, and hospitals
- Insight from our team of in-house industry experts
Public data
- Attendance and participation at major, worldwide meetings
- Public health systems and registries
- Clinical study data
- Analysis of company-published financial reports
Join Market Scope Today
Register A Corporate Account
Register A Clinical Account
A clinical account gives you access to survey participation and results, weekly polls, benchmark reports, a searchable news archive, and more on a personalized dashboard.